SANUWAVE Health, Inc. filed its quarterly report on Form 10-Q with the SEC on November 10, 2026, covering the period ended September 30, 2026, disclosing condensed consolidated balance sheet figures including a decline in cash and accounts receivable from year-end 2025 levels.
Key Highlights
- Cash position: Cash and cash equivalents stood at $6,569 thousand as of September 30, 2026, down from $11,959 thousand at December 31, 2025, according to the filing.
- Accounts receivable: Net accounts receivable were $4,965 thousand as of September 30, 2026 (net of allowance of $1,489 thousand), compared to $5,422 thousand (net of allowance of $1,265 thousand) at December 31, 2025.
- Inventory increase: Inventory rose to $6,724 thousand from $5,934 thousand at December 31, 2025.
- Total current assets: Total current assets were $19,299 thousand as of September 30, 2026, compared to $24,627 thousand at December 31, 2025.
- Shares outstanding: As of November 5, 2026, there were 8,602,309 shares of common stock issued and outstanding, par value $0.001 per share.
- Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, as indicated in the filing.
SANUWAVE Health Balance Sheet Trends Through September 30, 2026
SANUWAVE Health, Inc. (NASDAQ:SNWV), headquartered in Eden Prairie, MN, filed its Form 10-Q for the quarterly period ended September 30, 2026. According to the filing, cash and cash equivalents declined to $6,569 thousand from $11,959 thousand at December 31, 2025. The company also reported the addition of a secured revolving credit facility debt issuance costs line item of $39 thousand on the September 30, 2026 balance sheet, which was not present at year-end 2025.
The filing disclosed that accounts receivable, net of allowance, decreased to $4,965 thousand from $5,422 thousand at December 31, 2025, while the allowance itself increased to $1,489 thousand from $1,265 thousand over the same period. Inventory grew to $6,724 thousand from $5,934 thousand. Prepaid expenses and other current assets fell to $1,002 thousand from $1,312 thousand. These movements together resulted in total current assets of $19,299 thousand, compared to $24,627 thousand reported at December 31, 2025.
The filing contains forward-looking statements, which the company characterizes as subject to risks and uncertainties. Among the factors cited are "anticipated reimbursement levels from the Centers for Medicare and Medicaid Services for skin substitutes, allografts, or other advanced wound care products," the "emergence and growth of a secondary market for used Ultramist® systems," and the company's "ability to regain and maintain compliance with the Nasdaq listing requirements." The company stated that forward-looking statements are "based on management's estimates, projections and assumptions as of the date hereof" and that it "does not undertake, and expressly disclaims, any duty or obligation to revise or update any forward-looking statements."
What Was Disclosed
SANUWAVE Health filed a Form 10-Q for the quarter ended September 30, 2026, reporting cash of $6,569 thousand, total current assets of $19,299 thousand, inventory of $6,724 thousand, and 8,602,309 shares of common stock outstanding as of November 5, 2026.




Please wait processing your request...